Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 3/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825872 | 0.92 | TP53 (0.70) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL6095731 | 0.89 | TP53 (0.71) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL825563 | 0.89 | TP53 (0.71) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL7746552 | 0.88 | PDE4A (0.71) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL3558078 | 0.88 | TP53 (0.53) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL1193475 | 0.87 | TP53 (0.64) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL825658 | 0.87 | PDE4A (0.72) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL15252347 | 0.87 | TP53 (0.51) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL4919222 | 0.87 | PDE4A (0.60) | TP53KMT2AMEN1MAPTPDE4A | |
| SCHEMBL825454 | 0.86 | PDE4A (0.71) | TP53KMT2AMEN1MAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE | 2004-08-26 | — | — | US | claimed |
| EP-1246620-A4 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORP (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1246620-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORPORATION (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE | 2004-08-26 | — | — | US | disclosed |
| EP-1246620-A4 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1246620-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORPORATION (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | APEH, TNF, ACOX3 | TP53 4342/4885KMT2A 1504/4885MEN1 4531/4885 |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | TNF, APEH, ACOX3 | TP53 4236/4885KMT2A 1261/4885MEN1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.